Novo bets up to $1.4B on Orbis's oral macrocycle platform
- Orbis Medicines signed a multi-target discovery and license deal with Novo Nordisk worth up to $1.4B in upfront and milestone payments plus tiered royalties.
- Novo also takes a strategic equity stake in the private Copenhagen company; this is Orbis's first pharma partnership.
- The work uses Orbis's AI-enabled nGen platform to make macrocycles aimed at turning injectable cardiometabolic therapies into orals.
- Orbis reported preclinical oral bioavailability up to 18%; targets and disease areas beyond cardiometabolic were not disclosed.
💡 Points
This is Novo hedging its oral strategy beyond small-molecule GLP-1s and oral semaglutide: macrocycles are the bet that peptide-like potency can survive the gut. The headline number is mostly milestones, so the real signal is the equity stake and a multi-target structure that lets Novo test the platform cheaply. Lilly is also an Orbis backer, which tells you both obesity leaders want the same oral-peptide option.
Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo ↗